Atossa Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Atossa Therapeutics şirketinin toplam hissedar öz sermayesi $80.2M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $85.9M ve $5.7M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$79.53m
Eşitlik	US$80.16m
Toplam yükümlülükler	US$5.70m
Toplam varlıklar	US$85.86m

Son finansal sağlık güncellemeleri

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: YAG2 'nin kısa vadeli varlıkları ( $81.7M ) kısa vadeli yükümlülüklerini ( $5.7M ) aşıyor.

Uzun Vadeli Yükümlülükler: YAG2 un uzun vadeli yükümlülüğü bulunmamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: YAG2 borçsuzdur.

Borcun Azaltılması: YAG2 son 5 yıldır borcu bulunmamaktadır.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: YAG2 şirketinin mevcut serbest nakit akışına göre 3 yıldan fazla bir süre için yeterli nakit pistine sahip olduğu belirtiliyor.

Tahmini Nakit Akışı: YAG2 tarihsel oranlara göre serbest nakit akışı büyümeye veya küçülmeye devam ederse yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

Sağlıklı şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/10/27 19:56
Gün Sonu Hisse Fiyatı	2024/07/31 00:00
Kazançlar	2024/06/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Atossa Therapeutics, Inc. 9 Bu analistlerden 4, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Edward Woo	Ascendiant Capital Markets LLC
Louise Chen	Cantor Fitzgerald & Co.
Pooya Hemami	Edison Investment Research

Atossa Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Atossa Therapeutics Regain Compliance with Nasdaq Minimum Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2)

Atossa Therapeutics Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements

Atossa Therapeutics Receives Letter from NASDAQ Regarding Minimum Bid Price Requirement

Recent updates

Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z-Endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium

Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density

Atossa Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Atossa Therapeutics Reports Positive Karisma-Endoxifen Trial Results

Atossa Therapeutics, Inc Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer

Atossa Therapeutics Grants Additional Patent Protection for Endoxifen

Atossa Therapeutics, Inc. and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer

Forecast to breakeven in 2026

Atossa Therapeutics Completes Enrollment of 80Mg Pharmacokinetic Run-In Cohort in Phase 2 Evangeline Clinical Trial Evaluating (Z)-Endoxifen as A Neoadjuvant Treatment for Er+ / Her2- Breast Cancer

Atossa Therapeutics, Inc. Appoints Heather Rees as Chief Financial Officer

Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer

No longer forecast to breakeven

No longer forecast to breakeven

Atossa Therapeutics, Inc. Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment Model

Atossa Therapeutics, Inc. Announces Last Patient, Last Dose in Its Phase 2 Karisma-Endoxifen Clinical Trial

Atossa Therapeutics, Inc., Annual General Meeting, Jun 27, 2024

Atossa Therapeutics and Quantum Leap Healthcare Collaborative Announces I-SPY 2 Clinical Trial to Evaluate (Z-Endoxifen in Combination with Abemaciclib (VERZENIO®?) in Women with ER+/HER2- Breast Cancer

Atossa Therapeutics, Inc. Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen

New minor risk - Profitability

Less than half of directors are independent

Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for A U.S. Breast Cancer Patient

Atossa Therapeutics Regain Compliance with Nasdaq Minimum Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2)

Less than half of directors are independent

Atossa Therapeutics Appoints Tessa Cigler to Its Board of Directors

Atossa Therapeutics, Inc. Announces First Patient Dosed with Selective Estrogen Receptor Modulator in the Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

Forecast to breakeven in 2026

Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director

Atossa Therapeutics, Inc. Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial

Atossa Therapeutics, Inc. Appoints Jonathan Finn to Its Board of Directors

Atossa Therapeutics, Inc. Appoints Jonathan Finn to Its Board of Directors

Quantum Leap Healthcare Collaborative Initiates Landmark Phase 2 RECAST DCIS Platform Trial to Evaluate Alternative DCIS Treatments with Atossa Therapeutics, Havah Therapeutics, and the Menarini Group

Atossa Therapeutics Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

Insufficient new directors

Atossa Therapeutics, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements

Atossa Therapeutics, Inc. Provides Enrollment Update for Ongoing Phase 2 Karisma-Endoxifen Clinical Trial

Atossa Therapeutics and Quantum Leap Healthcare Provide Enrollment Update for (Z)-Endoxifen Arm of Ongoing I-SPY 2 Clinical Trial

Atossa Therapeutics, Inc. (NasdaqCM:ATOS) announces an Equity Buyback for $10 million worth of its shares.

Atossa Therapeutics, Inc. Completes Enrollment of Pharmacokinetic Run-In Cohort in Phase 2 Evangeline Clinical Trial Evaluating (Z-Endoxifen as A Neoadjuvant Treatment for Er+ / Her2- Breast Cancer

Atossa Therapeutics, Inc. Announces Executive Changes

Atossa Therapeutics, Inc. (NasdaqCM:ATOS) agreed to acquire 19.99% equity in Dynamic Cell Therapies, Inc. for $5 million.

Atossa Therapeutics, Inc. (NasdaqCM:ATOS) agreed to acquire 19.99% equity in Dynamic Cell Therapies, Inc. for $5 million.

Atossa Therapeutics, Inc. Appoints Richard Graydon as Interim Chief Medical Officer

Atossa Therapeutics, Inc. Receives Authorization from FDA to Initiate Its Phase 2 Study of Neoadjuvant (Z)-Endoxifen in Premenopausal Women with Er+/Her2- Breast Cancer

Atossa Therapeutics Receives Letter from NASDAQ Regarding Minimum Bid Price Requirement

Atossa Therapeutics, Inc. Appoints Dr. Paul Wabnitz to its Scientific Advisory Board

Atossa Therapeutics, Inc. Announces Dosing Completed in Part C of Atossa’s Phase 1/2a Study of AT-H201 in Healthy Volunteers

Insufficient new directors

Atossa Therapeutics, Inc. Announces Completion of Participants Enrollment in Part B of its Phase 1/2a Clinical Study of AT-H201 in Australia, Consisting of Multiple Ascending Dose Cohorts in Healthy Participants

Atossa Therapeutics, Inc., Annual General Meeting, May 13, 2022

No longer forecast to breakeven

Forecast to breakeven in 2024

Insufficient new directors

Atossa Therapeutics Announces Advancement to Part B of Clinical Study of AT-H201

Forecast to breakeven in 2024

Insufficient new directors

Atossa Therapeutics Begins Enrollment of Phase 2 Clinical Study of Oral Endoxifen in Sweden

Insufficient new directors

Insufficient new directors

Atossa Therapeutics Receives Approval from Swedish Ethics Review Authority to Initiate A Phase 2 Clinical Study of Oral Endoxifen

Atossa Therapeutics Receives Approval from Swedish Regulators to Initiate Phase 2 Clinical Study of Oral Endoxifen to Reduce Mammographic Breast Density

Atossa Therapeutics Announces Final Data from Phase 2 Endoxifen Breast Cancer Study Primary Endpoint Met: 65.1% Reduction in Biomarker Ki-67; Secondary Endpoint Met: Endoxifen Safe and Well Tolerated

Atossa Therapeutics to Release Final Data from Phase 2 Study of Endoxifen Administered to Breast Cancer Patients Prior to Surgery At A Webinar At 8 Am Pacific Time on June 9, 2021

Atossa Therapeutics, Inc. Announces Receipt of FDA Safe to Proceed Letter for Treatment of an Ovarian Cancer Patient with Oral Endoxifen Under Expanded Access Pathway

Atossa Therapeutics Announces Final Results from Phase 1 Clinical Study Showing Safety and Tolerability of AT-301 Nasal Spray Being Developed for COVID-19

Atossa Therapeutics, Inc.'s Phase 2 Endoxifen Breast Cancer Study Produces Substantially Positive Results Allowing Study to Be Halted Early

New 90-day high: €1.55

Atossa Therapeutics, Inc. has completed a Composite Units Offering in the amount of $20 million.

New 90-day low: €0.72

New 90-day low: €1.07

Atossa Therapeutics Announces Preliminary Results from Phase 1 Clinical Study Showing Safety and Tolerability of At-301 Nasal Spray Being Developed for Covid-19